Do’s and don’ts in evaluation of endoscopic screening for gastrointestinal cancers

Endoscopic screening for cancers of the esophagus, stomach, and colon has been introduced in many countries of the world. Endoscopic screening has the potential to reduce incidence and mortality of the target diseases, but may also be harmful and have unwanted side effects. Precise estimates of the magnitude of benefits and harms of endoscopic screening for cancer are a prerequisite for informed decision making for or against participation in screening for individuals in the target population. This paper outlines the most common pitfalls in the evaluation of screening and offers some recommendations for future studies.

• References

• 1 World Health Organization. GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx Accessed 3 February 2015
• 2 Stryker SJ, Wolff BG, Culp CE et al. Natural history of untreated colonic polyps. Gastroenterology 1987; 93: 1009-1013
• 3 Hofstad B, Vatn MH, Andersen SN et al. Growth of colorectal polyps: redetection and evaluation of unresected polyps for a period of three years. Gut 1996; 39: 449-456
• 4 Gustafsson L, Adami HO. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer 1989; 60: 132-141
• 5 Lieberman D. Colon-polyp surveillance – do patients benefit?. N Engl J Med 2014; 371: 860-861
• 6 Løberg M, Kalager M, Holme Ø et al. Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med 2014; 371: 799-807
• 7 Bretthauer M, Hoff G. Comparative effectiveness in cancer screening programmes. BMJ 2012; 344: e2864
• 8 Jorgensen KJ. Flawed methods explain the effect of mammography screening in Nijmegen. Br J Cancer 2011; 105: 592-593
• 9 Kalager M, Zelen M, Langmark F et al. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010; 363: 1203-1210
• 10 Holme Ø, Bretthauer M, Fretheim A et al. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev 2013; 9: CD009259
• 11 Hoff G, Grotmol T, Skovlund E et al. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009; 338: b1846
• 12 Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic” – screening and overdiagnosis. N Engl J Med 2014; 371: 1765-1767
• 13 Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012; 367: 1998-2005
• 14 Bretthauer M, Kalager M. Principles, effectiveness and caveats in screening for cancer. Br J Surg 2013; 100: 55-65
• 15 Corley DA, Jensen CD, Marks AR et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014; 370: 1298-1306
• 16 Dawwas MF. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014; 370: 2539-2540
• 17 Vainio H, Bianchini F eds IARC Handbooks of Cancer Prevention, Vol. 7. Breast Cancer Screening. Lyons: IARC Press; 2002
• 18 Selby JV, Friedman GD, Quesenberry Jr CP et al. A case–control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326: 653-657